Interestingly, these studies displayed greater expression of fibroblast growth factor receptor 3 (FGFR3) protein in HB tissue than in RCC, increasing the hypothesis that treatment with fibroblast growth factor pathway-blocking agents may benefit patients with HB. This evidence concerns the gene FGFR3 and hemoglobin measurement.